Our Pipeline: Highlighting the Promising Drugs in Development
GM2811 - Alcohol Use Disorder (AUD):
A novel approach to treating Alcohol Use Disorder, aiming to improve lives and reduce dependency. GM2811 represents a groundbreaking advancement in addressing AUD,
GM2812 - Opioid Use Disorder (OUD)
Targeting Opioid Use Disorder with groundbreaking pharmaceutical therapy. GM2812 stands at the forefront of our efforts to combat the opioid crisis, offering a new dimension in the treatment landscape for individuals grappling with OUD.
GM2813 - Gambling Disorder
Innovative solutions for combating Gambling Disorder. GM2813 represents a dedicated initiative to address the complexities of Gambling Disorder, offering a ray of hope for those entangled in the grip of compulsive gambling.
GM2814 - Mild Cognitive Impairment (MCI)
Addressing Mild Cognitive Impairment with advanced drug repurposing strategies. GM2814 symbolizes our commitment to enhancing cognitive health and function. By employing cutting-edge drug repurposing techniques,
Our Innovative Research Pipeline
Our innovative research pipeline underscores our dedication to pioneering pharmaceutical solutions that make a difference in the lives of individuals facing various challenges. Through these promising drug developments, we aim to contribute to a healthier, more resilient future.